Skip to main content
Jiangsu Bioperfectus Technologies Co., Ltd. logo

Jiangsu Bioperfectus Technologies Co., Ltd. — Investor Relations & Filings

Ticker · 688399 ISIN · CNE1000055B2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688399

About Jiangsu Bioperfectus Technologies Co., Ltd.

https://www.bioperfectus.com/

Jiangsu Bioperfectus Technologies Co., Ltd. specializes in the research, development, and manufacturing of molecular diagnostic solutions. The company provides a comprehensive portfolio of products, including real-time PCR diagnostic kits, automated nucleic acid extraction systems, and rapid test reagents. Its primary focus lies in the detection of infectious diseases, such as respiratory infections, sexually transmitted diseases, and vector-borne illnesses. Bioperfectus serves clinical laboratories, public health institutions, and research facilities. The company provides integrated laboratory workflows designed to enhance diagnostic efficiency and accuracy. Key product lines include solutions for HPV screening, influenza monitoring, and emerging pathogen detection, supported by high-throughput diagnostic platforms.

Recent filings

Filing Released Lang Actions
江苏硕世生物科技股份有限公司关于自愿披露取得医疗器械注册证的公告
Regulatory Filings
2026-05-06 Chinese
江苏硕世生物科技股份有限公司2025年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2025年年度报告摘要" which translates to "2025 Annual Report Summary". It contains detailed financial data for the year 2025, including total assets, net profit, revenue, and quarterly breakdowns. It also includes company business descriptions, industry analysis, shareholder information, and management discussion of financial results and risks. The length of the document (9493 characters) and the presence of substantive financial data and analysis indicate this is a report itself, not merely an announcement of a report. The content aligns with the characteristics of an Annual Report (10-K) as it covers company activity and full financial performance for the fiscal year. Therefore, the appropriate classification is Annual Report (10-K).
2026-04-22 Chinese
江苏硕世生物科技股份有限公司董事会审计委员会对会计师事务所2025年度履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the performance and supervision of the external audit firm for the fiscal year 2025. It details the audit firm's qualifications, the audit process, communication with management, and the committee's evaluation of the audit firm's work. The document references the 2025 annual audit and the audit report issued by the firm, but it is not the audit report itself nor the full annual report. Instead, it is a supervisory report on the audit firm's performance and the audit committee's oversight activities. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding full annual reports. The document length is 2289 characters, which is consistent with a detailed committee report rather than a brief announcement or certification. Therefore, the appropriate classification is AR with high confidence.
2026-04-22 Chinese
江苏硕世生物科技股份有限公司董事会2025年度对独立董事独立性自查情况的专项报告
Environmental & Social Information Classification · 100% confidence The document is titled "2025年度环境、社会和公司治理 (ESG) 报告" which translates to "2025 Environmental, Social and Governance (ESG) Report". It is issued by Jiangsu Bioperfectus Technologies Co., Ltd. The content includes detailed disclosures on environmental, social, and governance practices, sustainability governance, risk management, corporate governance, social responsibility, and related performance metrics for the fiscal year 2025. The document references ESG reporting standards and regulatory guidelines, such as Shanghai Stock Exchange self-regulatory guidelines for sustainability reports and GRI standards. It contains substantive data and narrative on ESG performance, governance structure, risk controls, and social impact, consistent with an ESG report. It is not an announcement or a brief summary but a full report with detailed content and data. Therefore, the document fits the category of Environmental & Social Information (ESG) report.
2026-04-22 Chinese
立信会计师事务所（特殊普通合伙）关于江苏硕世生物科技股份有限公司内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' for the fiscal year 2025. It is issued by a certified public accounting firm (立信会计师事务所) and includes an audit opinion on the effectiveness of the company's internal control over financial reporting as of December 31, 2025. The content focuses on the audit of internal controls rather than the full annual financial statements or comprehensive company activity. The document length is about 3014 characters, which is consistent with a standalone audit report rather than a full annual report. There is no indication that this is an announcement or a certification letter; it contains substantive audit content. Therefore, this document fits the category of an Audit Report / Information (AR).
2026-04-22 Chinese
江苏硕世生物科技股份有限公司审计报告及财务报表
Regulatory Filings
2026-04-22 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.